About this trial
Ovarian stimulation (OS) is a key component of IVF, aimed at increasing oocyte yield and improving embryo development potential. While early protocols relied solely on FSH, newer approaches incorporate hMG and LH-based stimulation, allowing more individualized treatments for specific patient populations. Evidence suggests that hMG and recombinant FSH (rFSH) have comparable effectiveness in stimulation outcomes, and current guidelines support the use of both. However, the impact of different gonadotropins on embryo quality remains unclear, with mixed findings across protocols. Given the increasing use of combined rFSH and hMG and the limited data in PPOS protocols, this study proposes a randomized controlled trial to compare embryo quality between two different rFSH-hMG dosing strategies.
Eligibility criteria
Qualifiers
Undergoing preimplantation genetic screening cycles
AMH 0.5 - 3.5 ng/ml or AFC 5-20 (results of up to one year will be valid)
BMI 18.5 - 30 Kg/m2
Normal karyotypes in both partners
Disqualifiers
Previous poor ovarian response (≤3 oocytes with a conventional stimulation protocol), according to Bologna criteria
Severe male factor requiring TESE (testicular sperm extraction)
Administration of any other drug potentially interfering with the treatment
Contraindication for hormonal treatment
Trial design
Treatments tested in this trial
- 10 mcg of follitropin-delta + 150 of hMG
- 5 mcg of follitropin-delta + 225 of hMG
Treatment groups
Sponsors and collaborators
Fundacion Dexeus
Lead sponsor
Ferring Pharmaceuticals
Collaborator